Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that the company is now enrolling patients in Phase III clinical trials for CM-AT, its autism treatment, at ten sites across the country. The sites are:
- Mount Sinai School of Medicine, New York City
- Drexel University, Philadelphia
- University of Texas, Houston
- Indiana University, Purdue University, Indianapolis
- Ohio State University, Columbus
- Louisiana State University, Shreveport
- Southwest Autism Research and Resource Center (SARRC), Phoenix, Arizona
- University of North Carolina, Chapel Hill
- Pennsylvania State University, Hershey Medical Center, Hershey, Pennsylvania
- Lake Mary Pediatrics, Orange City, Florida
Curemark's Phase III trials for CM-AT encompass 12 sites nationally with a total 170 children.
"We have six new trial sites that are now active and recruiting patients – New York, Philadelphia, Houston, Indianapolis, Columbus and Shreveport. These are in addition to the four that we announced had opened enrollment in October and November," said Dr. Joan Fallon, Curemark founder and CEO. "We're moving very rapidly with our clinical trial program and anticipate that the remaining sites will be initiating enrollment soon."